General Information
BounceWatch is an independent company data service, not affiliated with Soligenix, Inc.. To contact Soligenix, Inc., visit soligenix.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Soligenix, Inc. compare?
A PDF of Soligenix, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Soligenix, Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Soligenix, Inc. on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biopharma
About Soligenix, Inc.
Business keywords: biopharmaceutical company, rare diseases, photodynamic therapy, vaccine development, oncology, gastrointestinal disorders, innovative therapies, biodefense, infectious diseases, drug development, clinical research, regulatory approval, government funding, late-stage development
Funding Rounds & Investors (15)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $4.75M | - |
|
18 Apr 2024 |
| Post IPO Equity | $8.50M | - |
|
05 May 2023 |
| Post IPO Debt | $1.20M | 1 | 15 Nov 2022 | |
| Grant | $2.60M | 1 |
U.S. Food and Drug Administration
|
06 Sep 2022 |
| Grant | $1.40M | 2 | 19 Apr 2022 | |
| Grant | $1.50M | 1 |
National Institutes of Health
|
28 Dec 2020 |
| Grant | $1.50M | 1 |
National Institutes of Health
|
18 Sep 2017 |
| Post IPO Equity | $2.50M | - |
|
14 Aug 2017 |
| Grant | $634.00K | 2 |
National Institute of Allergy and Infectious Diseases, Biomedical Advanced Research and Development Authority (BARDA)
|
25 Jul 2016 |
| Venture Round | $10.00M | 1 | 03 Aug 2015 |
Soligenix, Inc. Alternatives & Competitors
View All AlternativesClinical-stage biopharma company developing novel RNA-modulating drug candidates to treat rare and u...
A late-stage clinical biopharmaceutical company focused on developing novel therapies for a range of...
Developing innovative therapies to treat and cure rare metabolic diseases
FAQ About Soligenix, Inc.
Source: BounceWatch company record for Soligenix, Inc., https://www.bouncewatch.com/company/soligenix, updated 9 June 2026. When citing, please name BounceWatch and link this page.